117 related articles for article (PubMed ID: 23013267)
1. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
Asklund T; Henriksson R; Axelsson J; Bergström Å; Kasper M; Ögren M; Toftgård R; Riklund KÅ
Acta Oncol; 2013 May; 52(4):862-6. PubMed ID: 23013267
[No Abstract] [Full Text] [Related]
2. [Treatment of an extraneural metastasized medulloblastoma].
Huber A; Bohl J; Gutjahr P
Klin Padiatr; 1990; 202(3):186-7. PubMed ID: 2355723
[TBL] [Abstract][Full Text] [Related]
3. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.
Climans SA; Macdonald DR; Sutherland DE; Mason WP
BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230
[TBL] [Abstract][Full Text] [Related]
4. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T
Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival in a child with extraneural metastasis from medulloblastoma treated with chemo-radiotherapy.
Paulino AC
Med Pediatr Oncol; 2003 Jun; 40(6):396-7. PubMed ID: 12692812
[No Abstract] [Full Text] [Related]
7. SHH inhibitors for the treatment of medulloblastoma.
Samkari A; White J; Packer R
Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
[TBL] [Abstract][Full Text] [Related]
8. [Extracranial metastases from medulloblastoma: report of four cases (author's transl)].
Donati E; Mazza C; Campostrini F; Di Marco A; Griso C; Carbognin S; Pasqualin A
Radiol Med; 1980 Dec; 66(12):959-66. PubMed ID: 7232783
[TBL] [Abstract][Full Text] [Related]
9. Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
Bonney PA; Santucci JA; Maurer AJ; Sughrue ME; McNall-Knapp RY; Battiste JD
J Clin Neurosci; 2016 Apr; 26():161-3. PubMed ID: 26777082
[TBL] [Abstract][Full Text] [Related]
10. Radiological study of skeletal metastases from cerebellar medulloblastoma.
Banna M; Lassman LP; Pearce GW
Br J Radiol; 1970 Mar; 43(507):173-9. PubMed ID: 5309319
[No Abstract] [Full Text] [Related]
11. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
[TBL] [Abstract][Full Text] [Related]
12. [High risk cerebellar medulloblastoma: the use of high doses of chemotherapy].
Benito Bernal A; Villa Alcázar M; Díaz Pérez MA; Madero López L
An Esp Pediatr; 1997 Dec; 47(6):647-50. PubMed ID: 9575128
[No Abstract] [Full Text] [Related]
13. Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma.
Roesler R; de Farias CB; Brunetto AT; Gregianin L; Jaeger M; Nör C; Thomaz A
Neuro Oncol; 2022 Jul; 24(7):1210-1211. PubMed ID: 35552442
[No Abstract] [Full Text] [Related]
14. Vismodegib and Physeal Closure in a Pediatric Patient.
Lucas JT; Wright KD
Pediatr Blood Cancer; 2016 Nov; 63(11):2058. PubMed ID: 26864592
[No Abstract] [Full Text] [Related]
15. Clinical experience with Hedgehog pathway inhibitors.
Low JA; de Sauvage FJ
J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
[TBL] [Abstract][Full Text] [Related]
16. [Extracranial extraneural metastasizing brain tumor].
Elmohamed A; Hempel KJ; Hinzpeter T
Pathologe; 1987 Jan; 8(1):56-60. PubMed ID: 3562412
[No Abstract] [Full Text] [Related]
17. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.
Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D
Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892
[TBL] [Abstract][Full Text] [Related]
18. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
19. Brief report: Medulloblastoma with widespread skeletal metastases presenting with hypercalcemia.
Akyüz C; Yalçin B; Kutluk T; Cila A; Büyükpamukçu M
Med Pediatr Oncol; 1999 Aug; 33(2):126-8. PubMed ID: 10398191
[No Abstract] [Full Text] [Related]
20. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
